CTLT - Catalent, Inc.
52.76 +0.58 (1.12%)
After hours: 4:26PM EST
| Previous Close | 53.09 |
| Open | 53.11 |
| Bid | 52.15 x 800 |
| Ask | 52.17 x 900 |
| Day's Range | 52.02 - 53.44 |
| 52 Week Range | 29.23 - 58.38 |
| Volume | 751,485 |
| Avg. Volume | 663,362 |
| Market Cap | 7.6B |
| Beta (3Y Monthly) | 1.68 |
| PE Ratio (TTM) | 55.39 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Insider Monkey
Hedge Funds Piled Into Catalent Inc (CTLT) Just In Time
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
- Simply Wall St.
With EPS Growth And More, Catalent (NYSE:CTLT) Is Interesting
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
- Thomson Reuters StreetEvents
Edited Transcript of CTLT earnings conference call or presentation 5-Nov-19 1:15pm GMT
Q1 2020 Catalent Inc Earnings Call
- TipRanks
3 Monster Growth Stocks That Are Still Undervalued
For growth stocks, Wall Street pros suggest looking at the bigger picture. We mean taking a step back and searching for names capable of rewarding investors for years to come rather than in just the short-term. However, finding these stocks with explosive growth prospects isn’t always easy.That’s where TipRanks.com comes in. Using the platform’s in-depth market data, we were able to zero in on 3 stocks set to see huge gains in the long-run. Having earned enough support from the Street’s analysts in the last three months, all of these names have “Strong Buy” consensus ratings.If that wasn’t captivating enough, analysts note that each of the stocks’ strong growth narratives aren’t fully factored into their share prices, representing a compelling entry point.With this in mind, let’s dive in. Avalara, Inc. (AVLR) Avalara offers customers automated and cloud-based software to make it easier to comply with ever-changing tax laws. With another solid quarterly performance under its belt and an already posted year-to-date gain of 128%, analysts believe AVLR is still undervalued as it’s right on track to deliver massive returns.During its most recent quarter, AVLR was able to report a revenue and earnings beat thanks to substantial customer additions. We’re talking 810 new customers added vs J.P. Morgan analyst Sterling Auty’s estimate of 300. Not to mention the company reached an all-time high net retention rate of 113% and management guided around 25% revenue growth for 2020\. While the results represented a loss, Auty tells investors not to fear as AVLR is just getting started. “We think the stock still has room to move higher driven by these secular growth factors and a valuation that is below many other premium names,” he commented. The five-star analyst adds that its 2020 revenue guidance “likely provides ample opportunity to under promise and over deliver”. As a result, Auty kept his Buy rating and $104 price target. This target conveys his confidence in AVLR’s ability to climb 46% higher over the next twelve months. (To watch Auty’s track record, click here) Like Auty, the rest of the Street has high hopes for AVLR. As 100% of the analysts that have published ratings in the last three months were bullish, AVLR is a ‘Strong Buy’. Additionally, its $98 average price target indicates 37% upside potential. (See Avalara stock analysis on TipRanks) The Trade Desk, Inc. (TTD)This year has seen Trade Desk cement its status as a stand-out growth name, rising 68% year-to-date to be exact. Even though shares have stumbled in the last week, several top analysts cite the online advertising marketplace as a force to be reckoned with.According to its third quarter results, it’s clear why TTD is on Wall Street’s radar. The company surpassed the consensus estimates for both revenue and earnings as well as upped its guidance for the fourth quarter. While this guidance was disappointing for some investors, SunTrust Robinson analyst Youssef Squali argues that TTD is holding up well against the expanding total available market and has been steadily improving margins. Squali also highlights TTD based on its stellar 95%-plus customer retention rate in the quarter as well as its continued efforts to capitalize on international opportunities and a more-data driven approach from agencies and brands. Meanwhile, RBC Capital’s Mark Mahaney believes that TTD is “one of the best positioned stocks to benefit from the shift to streaming” thanks to its rapidly growing connected TV (CTV) segment. The CTV business has grown about 145% year-over-year following many previous quarters of triple digit growth rates. “We estimate CTV to account for close to 20% of TTD’s Revenue in 2020 – and the recent deal with Amazon Fire TV / APS is further evidence of their strong positioning,” he noted. Bearing this in mind, both of the five-star analysts maintain a bullish thesis. Out of the two, Squali sees the largest potential twelve-month gain, with the forecast coming in at 46%. (To watch Squali’s track record, click here) In general, other analysts are on the same page. 6 Buy ratings and 2 Holds assigned in the last three months add up to a ‘Strong Buy’ consensus. The average price target of $247 brings the upside potential to 26%. (See Trade Desk stock analysis on TipRanks) Catalent Inc. (CTLT)Catalent is known for providing integrated services, superior drug delivery technologies and manufacturing solutions to help launch pharmaceuticals, biologics and other consumer health products. With it starting off its fiscal year on a positive note and its shares already up 59% year-to-date, the Street has its eye on CTLT.CTLT’s solid fiscal Q1 2020 performance, which included a 2% EBITDA beat and 11% organic growth, was fueled largely by its Paragon acquisition. In addition, management reaffirmed ibuprofen supply stability for Softgel by pointing out that it has alternative sources to mitigate any possible disruptions in the future. It should also be noted that its strength in the oral drug delivery business stands to drive significant gains for CTLT. All of this played into UBS analyst Daniel Brennan’s conclusion that the company is in it for the long-haul. While acknowledging the tempered stock reaction to these developments, he remains optimistic about CTLT’s prospects. “We see the lack of share price reaction as an opportunity to reiterate our buy rating,” Brennan explained. Along with his Buy rating, the analyst set a $66 price target. Based on this target, shares could surge 33% over the next twelve months. (To watch Brennan’s track record, click here) Similarly, the rest of the Street likes what it’s seeing. With 4 Buy ratings compared to 1 Hold issued in the last three months, CTLT has a ‘Strong Buy’ analyst consensus. On top of this, its $61 average price target implies 23% upside potential. (See Catalent stock analysis on TipRanks)
- Zacks
Catalent (CTLT) Surpasses Q1 Earnings and Revenue Estimates
Catalent (CTLT) delivered earnings and revenue surprises of 8.33% and 4.45%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More
Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.
- GuruFocus.com
Ken Fisher's Top 5 Buys for the 3rd Quarter
2 of the guru’s new positions are in ETFs Continue reading...
- Simply Wall St.
The Catalent (NYSE:CTLT) Share Price Has Gained 125%, So Why Not Pay It Some Attention?
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
- Zacks
Earnings Preview: Catalent (CTLT) Q1 Earnings Expected to Decline
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?
CTLT vs. NBIX: Which Stock Is the Better Value Option?
- American City Business Journals
Paragon growing quickly toward 1,000 employees after Catalent acquisition
Paragon Gene Therapy has grown its Maryland employee base to about 750, up from around 400 in April when the biotech announced it would be acquired by New Jersey drug maker Catalent Inc. Paragon, formerly Paragon Bioservices Inc., has been growing rapidly in Greater Baltimore. About 350 of Paragon's employees are based out of a research and development space in the University of Maryland BioPark in Baltimore. The rest are stationed in a new 150,000-square-foot headquarters and manufacturing facility in Anne Arundel County, which opened earlier this year.
- Zacks
Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 6.2%
Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Insider Monkey
Is Catalent Inc (CTLT) A Good Stock To Buy?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
- Zacks
CTLT or NBIX: Which Is the Better Value Stock Right Now?
CTLT vs. NBIX: Which Stock Is the Better Value Option?
- Simply Wall St.
Is Catalent, Inc.'s (NYSE:CTLT) High P/E Ratio A Problem For Investors?
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. We'll apply a basic...
- Simply Wall St.
Does Catalent (NYSE:CTLT) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- Zacks
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
- Zacks
Lannett (LCI) Hits 52-Week High, Can the Run Continue?
Lannett (LCI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Zacks
Catalent (CTLT) Upgraded to Buy: Here's Why
Catalent (CTLT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Thomson Reuters StreetEvents
Edited Transcript of CTLT earnings conference call or presentation 27-Aug-19 12:15pm GMT
Q4 2019 Catalent Inc Earnings Call
- Benzinga
Catalent Analyst Cites Valuation Concerns In Downgrade
KeyBanc Capital Market's bull case for Catalent Inc (NYSE: CTLT) has come to an end. Catalent reported in-line fourth-quarter results that were highlighted by a 4% organic revenue growth and "stable" EBITDA, Hooker said in a Tuesday downgrade note. The company ended the fiscal year on an encouraging note, with $646 million of development revenue at an estimated mid-to-high-single-digit organic growth rate, he said.
- Investor's Business Daily
This Surging Medical Stock Beats Views, But Shares Take A Breather
Catalent stock dipped Tuesday after outperforming fiscal fourth-quarter expectations. Catalent earnings rose to 70 cents a share as sales climbed 8% in constant currency to $725.7 million.
Motley FoolCatalent Inc (CTLT) Q4 2019 Earnings Call Transcript
CTLT earnings call for the period ending June 30, 2019.
- Zacks
Catalent (CTLT) Surpasses Q4 Earnings and Revenue Estimates
Catalent (CTLT) delivered earnings and revenue surprises of 9.38% and 0.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Benzinga
Catalent Reports Q4 Earnings Beat
Catalent (NYSE: CTLT ) reported fourth-quarter earnings of 70 cents per share, which beat the analyst consensus estimate of 64 cents by 9.37%. This is a 4.48% increase over earnings of 67 cents per share ...
